Argenx Vyvgart fails Phase 3 Sjögren's trial, stock likely to react

Argenx announced that Vyvgart (efgartigimod) failed to meet the primary endpoint in a Phase 3 trial for Sjögren's disease, showing no significant benefit over placebo. This is an unusual setback for the drug, which is already approved for myasthenia gravis and is a key growth driver. The failure raises uncertainty about the drug's expansion into new indications and is likely to pressure Argenx's shares.